AI Article Synopsis

  • Identifying cryptic pockets in proteins can reveal hidden binding sites, offering new avenues for drug development, particularly in challenging targets such as KRAS, which was thought to be "undruggable."
  • The discovery of the Switch-II cryptic pocket in the KRAS mutant has led to FDA-approved cancer treatments, highlighting the clinical relevance of these pockets.
  • A novel approach using weighted ensemble molecular dynamics simulations was employed to explore these cryptic pockets in KRAS, analyzing over 400 microseconds of simulations and validating the method's ability to predict binding sites while examining the mechanics of ligand interactions.

Article Abstract

Identification of cryptic pockets has the potential to open new therapeutic opportunities by discovering ligand binding sites that remain hidden in static apo structures of a target protein. Moreover, allosteric cryptic pockets can become valuable for designing target-selective ligands when the natural ligand binding sites are conserved in variants of a protein. For example, before an allosteric cryptic pocket was discovered, KRAS was considered undruggable due to its smooth surface and conservation of the GDP/GTP binding pocket across the wild type and oncogenic isoforms. Recent identification of the Switch-II cryptic pocket in the KRAS mutant and FDA approval of anticancer drugs targeting this site underscores the importance of cryptic pockets in solving pharmaceutical challenges. Here, we present a newly developed approach for the exploration of cryptic pockets using weighted ensemble molecular dynamics simulations with inherent normal modes as progress coordinates applied to the wild type KRAS and the G12D mutant. We performed extensive all-atomic simulations (>400 μs) with and without several cosolvents (xenon, ethanol, benzene), and analyzed trajectories using three distinct methods to search for potential binding pockets. These methods have been applied as a proof-of-concept to KRAS and have shown they can predict known cryptic binding sites. Furthermore, we performed ligand-binding simulations of a known inhibitor (MRTX1133) to shed light on the nature of cryptic pockets in KRAS and the role of conformational selection vs induced-fit mechanism in the formation of these cryptic pockets.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558672PMC
http://dx.doi.org/10.1021/acs.jcim.4c01435DOI Listing

Publication Analysis

Top Keywords

cryptic pockets
28
binding sites
12
cryptic
9
exploration cryptic
8
pockets
8
normal modes
8
ligand binding
8
allosteric cryptic
8
cryptic pocket
8
wild type
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!